InSilicoMinds

𝗜𝗺𝗮𝗴𝗶𝗻𝗲 𝗮 𝗳𝘂𝘁𝘂𝗿𝗲 🧠 𝘄𝗵𝗲𝗿𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗱𝗿𝘂𝗴𝘀 𝗮𝗻𝗱 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 𝗿𝗲𝗮𝗰𝗵 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗺𝗼𝗿𝗲 𝗿𝗮𝗽𝗶𝗱𝗹𝘆, 𝗺𝗶𝗻𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗿𝗶𝘀𝗸𝘀 𝗮𝗻𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗼𝘀𝘁𝘀. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝘁𝗵𝗲 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗶𝗻 𝘀𝗶𝗹𝗶𝗰𝗼 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗮 𝗳𝗶𝗲𝗹𝗱 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲. 💊🔬 At the forefront of this revolution are 𝗶𝗻 𝘀𝗶𝗹𝗶𝗰𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 (𝗜𝗦𝗖𝗧𝘀), 𝘄𝗵𝗶𝗰𝗵 𝘂𝘁𝗶𝗹𝗶𝘇𝗲 𝘀𝗼𝗽𝗵𝗶𝘀𝘁𝗶𝗰𝗮𝘁𝗲𝗱 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿 𝗺𝗼𝗱𝗲𝗹𝘀 𝘁𝗼 𝗿𝗶𝗴𝗼𝗿𝗼𝘂𝘀𝗹𝘆 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲 𝘁𝗵𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝗮𝗻𝗱 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀, 𝘁𝗵𝗲𝗿𝗲𝗯𝘆 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗿𝗲𝗹𝗶𝗮𝗻𝗰𝗲 𝗼𝗻 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗶𝗺𝗮𝗹 🐁 𝗮𝗻𝗱 𝗵𝘂𝗺𝗮𝗻 👥 𝘁𝗿𝗶𝗮𝗹𝘀. 𝗜𝗦𝗖𝗧𝘀 𝗲𝗺𝗽𝗹𝗼𝘆 𝘀𝘂𝗯𝗷𝗲𝗰𝘁-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲𝘀 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝘃𝗶𝗿𝘁𝘂𝗮𝗹 𝗰𝗼𝗵𝗼𝗿𝘁𝘀, 𝗺𝗶𝗺𝗶𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿 𝗼𝗳 𝗿𝗲𝗮𝗹 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. This approach is already gaining recognition, with the FDA accepting an #insilicomodel as a replacement for #animal testing in the development of artificial pancreas #technology. 🏥 In 2008, the FDA authorized the use of an in silico simulation for the preclinical #safety assessment of control #algorithms for artificial pancreas systems, following extensive validation. This system, developed by the JDRF Artificial Pancreas Consortium, remains a primary test bed for closed-loop control algorithms #today. This example marks a broader trend toward incorporating #modeling and #simulation into regulatory evaluations. 📊 Between 2015 and 2016, both the US Congress and European Parliament recommended that #regulatory agencies include #modelingandsimulation as primary evidence sources in their processes. The FDA is also supporting the use of #insilico simulations in various stages of product #development, such as assessing MRI compatibility for pacemakers and evaluating the use of #virtualpatients alongside real clinical data. 🧑⚕️ At InSilicoMinds, we are dedicated to pioneering ISCTs to shape a healthier future. ✨ Visit www.insilicominds.com to explore how we are utilizing in silico clinical trials to advance the frontiers of medicine. 💻🔍 #ClinicalTrials #DrugDevelopment #MedicalDevices #Innovation #FutureofMedicine InSilicoTrials

A significant #challenge in pharmaceutical development is ensuring that new drug candidates reach therapeutic levels in the body. This is particularly problematic for poorly soluble #drugs, which exhibit limited dissolution in bodily fluids, hindering their absorption and overall effectiveness. 𝐒𝐡𝐨𝐜𝐤𝐢𝐧𝐠𝐥𝐲, 40% 𝐨𝐟 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝'𝐬 𝐭𝐨𝐩 𝐨𝐫𝐚𝐥 𝐝𝐫𝐮𝐠𝐬 𝐟𝐚𝐥𝐥 𝐢𝐧𝐭𝐨 𝐭𝐡𝐢𝐬 𝐜𝐚𝐭𝐞𝐠𝐨𝐫𝐲 (𝐁𝐂𝐒 𝐂𝐥𝐚𝐬𝐬 𝐈𝐈 𝐨𝐫 𝐈𝐕), 𝐢𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐧𝐠 𝐚 𝐰𝐢𝐝𝐞𝐬𝐩𝐫𝐞𝐚𝐝 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 𝐰𝐢𝐭𝐡 𝐟𝐚𝐫-𝐫𝐞𝐚𝐜𝐡𝐢𝐧𝐠 𝐜𝐨𝐧𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐞𝐬. The failure to address solubility issues early in the drug development process contributes to high attrition rates, resulting in significant #financial losses and delays in bringing new medicines to #market. This not only impacts the profitability of #pharmaceutical companies but, more importantly, delays access to potentially life-saving #treatments for patients. In silico predictive dissolution #modeling is the ultimate solution for tackling poorly soluble drugs. By simulating dissolution in #biorelevant media, it helps scientists quickly spot solubility challenges and test formulation strategies virtually. This #accelerates formulation optimization, cuts development #costs, and speeds up time to market. 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐚𝐭 𝐢𝐧𝐟𝐨@𝐢𝐧𝐬𝐢𝐥𝐢𝐜𝐨𝐦𝐢𝐧𝐝𝐬.𝐜𝐨𝐦 𝐭𝐨 𝐬𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐢𝐧 𝐬𝐢𝐥𝐢𝐜𝐨 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐚𝐧𝐝 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐰𝐞 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩 𝐲𝐨𝐮 𝐨𝐯𝐞𝐫𝐜𝐨𝐦𝐞 𝐬𝐨𝐥𝐮𝐛𝐢𝐥𝐢𝐭𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. #DrugSolubility #DrugDevelopment #PharmaceuticalIndustry #InSilicoModeling #PredictiveModeling #Bioavailability #BCS #PharmaceuticalScience #Biotechnology #Innovation InSilicoTrials

𝐀𝐈 𝐓𝐚𝐤𝐞𝐬 𝐂𝐞𝐧𝐭𝐞𝐫 𝐒𝐭𝐚𝐠𝐞 𝐚𝐭 𝐭𝐡𝐞 2024 𝐍𝐨𝐛𝐞𝐥 𝐏𝐫𝐢𝐳𝐞 𝐀𝐰𝐚𝐫𝐝𝐬! ✨💻 This year, AI, or the humans that contribute to it, are making waves across multiple disciplines, with two major Nobel Prizes awarded to AI innovations! In addition to the Nobel Prize in Chemistry for groundbreaking advancements in computational chemistry—particularly protein folding—AI also claimed the Nobel Prize in Physics for its revolutionary contributions to artificial neural networks. This marks a historic moment, highlighting AI’s profound impact on both #science and #technology. Congratulations 🎊 to the 2024 Nobel Prize winners for their outstanding contributions! David Baker was honored for his work in computational protein design in the field of #Chemistry, alongside Demis Hassabis and John Jumper, both recognized for their significant advancements in protein structure prediction. In the realm of #Physics, John J. Hopfield and Geoffrey E. Hinton were celebrated for their foundational discoveries and inventions that enable #machinelearning with artificial #neuralnetworks. At InSilicoMinds, we are absolutely ecstatic about these wins! 🏆 The recognition of AI’s transformative role in #proteinfolding and #computationalchemistry emphasizes how these technologies are hyper-accelerating and optimizing the pharmaceutical development process. AI’s ability to simulate #protein structures and predict their behavior with precision is revolutionizing #drugdiscovery, making therapies safer, more effective, and personalized for patients. ✨ As other areas and applications of AI in Pharma continue to grow, we are thrilled to be actively participating in its continued #evolution and #adoption. #AI #NobelPrize #ComputationalChemistry #ProteinFolding #ComputationalModeling #ArtificialNeuralNetworks #DrugDiscovery #Pharmaceutical #Innovation #InSilicoMinds #Biotechnology #LifeSciences InSilicoTrials

𝗧𝗵𝗲 𝗗𝗮𝘁𝗮 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗶𝗻 𝗔𝗜-𝗗𝗿𝗶𝘃𝗲𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 🧑💻💊 The pharmaceutical industry is experiencing a paradigm shift, with #data emerging as the new gold standard. The integration of Artificial Intelligence into #drugdiscovery processes is revolutionizing how data is utilized, analyzed, & interpreted. Despite the vast amounts of biomedical data generated daily, only a fraction is effectively utilized: 🔹The healthcare industry generates approximately 30% of the world's data volume, amounting to about 2,314 exabytes in 2020 that is equivalent to streaming music non-stop for over 2 billion years! That's like starting your playlist when the first multicellular life appeared on Earth & letting it run until now... 400 times over! 🔹However, it's estimated that only about 15-20% of this data is being utilized effectively in healthcare processes, including drug discovery. 🔹Approximately 80% of health data remains unstructured & difficult to analyze using traditional methods. AI is dramatically enhancing the speed & accuracy of drug discovery: 🔸Advanced AI systems can screen millions of compounds in silico, significantly faster than traditional methods. 🔸AI has the potential to reduce early-stage drug discovery timelines from 4-5 years to 1-2 years. 🔸AI-powered analysis of historical data has shown improvements in target identification accuracy, with some studies reporting up to 25-30% increase. 🔸Predictive models are estimated to potentially increase the success rate of drugs entering clinical trials by 15-25%. The financial impact of AI in drug discovery is substantial: 🔹AI-driven drug discovery is projected to potentially reduce drug development costs by $300-400 million per drug. 🔹Overall, AI could help reduce drug discovery costs by up to 20-30%. 🔹The market for AI in drug discovery is expected to grow from approximately $700 million in 2018 to $20 billion by 2025. While the potential is enormous, challenges remain: 🔸Integrating diverse data types (genomic, clinical, real-world) remains a significant hurdle. 🔸AI systems that can successfully integrate these diverse data types are showing promising improvements in predictive accuracy for drug efficacy. 🔸Ensuring the trustworthiness of algorithms, maintaining data integrity, achieving model transparency, & upholding ethical principles 🔸Ensuring high-quality, reliable training data is critical to avoid the "garbage in, garbage out" pitfall that can undermine AI models. ✨ Explore how we're leveraging data & AI to drive innovation in drug discovery and development at InSilicoMinds.com #DataRevolution #AIinDrugDiscovery #HealthcareInnovation #InsilicoMinds InSilicoTrials

🔍 𝐄𝐯𝐞𝐫 𝐰𝐨𝐧𝐝𝐞𝐫𝐞𝐝 𝐡𝐨𝐰 𝐈𝐧 𝐒𝐢𝐥𝐢𝐜𝐨 𝐦𝐨𝐝𝐞𝐥𝐬 𝐜𝐚𝐧 𝐢𝐦𝐩𝐚𝐜𝐭 𝐭𝐡𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐝𝐢𝐬𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐬𝐚𝐟𝐞 𝐬𝐩𝐚𝐜𝐞𝐬 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬? In a recent project, we explored the possibility of establishing a dissolution-safe space without conducting an actual BA (Bioavailability) study. Using advanced computational modeling and simulation techniques, we discovered some remarkable results. But the true impact? Well, that's something you’ll need to join our 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐨𝐧 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 27𝐭𝐡 to find out. Join us to uncover the full story behind how In Silico models are reshaping drug development—and why they’re the future of pharmaceutical innovation. 🔗 𝑹𝒆𝒈𝒊𝒔𝒕𝒆𝒓 𝑵𝒐𝒘: https://lnkd.in/gxfXp7S6 𝑮𝒆𝒕 𝒓𝒆𝒂𝒅𝒚 𝒕𝒐 𝒅𝒊𝒗𝒆 𝒊𝒏𝒕𝒐 𝒊𝒏 𝒔𝒊𝒍𝒊𝒄𝒐 𝒄𝒂𝒔𝒆 𝒔𝒕𝒖𝒅𝒊𝒆𝒔 𝒂𝒏𝒅 𝒖𝒏𝒍𝒐𝒄𝒌 𝒕𝒉𝒆 𝒇𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝒅𝒓𝒖𝒈 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒘𝒊𝒕𝒉 𝑨𝑰-𝒑𝒐𝒘𝒆𝒓𝒆𝒅 𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏𝒔. 𝑫𝒐𝒏’𝒕 𝒎𝒊𝒔𝒔 𝒊𝒕! #Webinar #pharma #drugdevelopment #ModelingAndSimulation #RegulatoryAffairs #Biosimilars #Generics #InSilico #biotechnology #LifeSciences #freewebinar InSilicoTrials

💡 𝐅𝐚𝐜𝐢𝐧𝐠 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐢𝐧𝐠 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬? AI has the power to revolutionize the way generics are developed, making them #faster, more #efficient, and cost #effective. Join our 𝐅𝐑𝐄𝐄 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 on S̳e̳p̳t̳e̳m̳b̳e̳r̳ ̳2̳7̳t̳h̳ to unlock #insights into how AI and in silico modeling are reshaping generic drug development. Don't miss out on key #industry trends and #strategies to stay ahead! ✨ 🔗 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘕𝘰𝘸: https://lnkd.in/gxfXp7S6 📱 Scan the QR Code for easy registration! 𝑳𝒆𝒂𝒓𝒏 𝒉𝒐𝒘 𝒕𝒐 𝒕𝒓𝒂𝒏𝒔𝒇𝒐𝒓𝒎 𝒚𝒐𝒖𝒓 𝒅𝒓𝒖𝒈 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒆𝒇𝒇𝒐𝒓𝒕𝒔 𝒘𝒊𝒕𝒉 𝒄𝒖𝒕𝒕𝒊𝒏𝒈-𝒆𝒅𝒈𝒆 𝑨𝑰. 𝑺𝒆𝒂𝒕𝒔 𝒂𝒓𝒆 𝒇𝒊𝒍𝒍𝒊𝒏𝒈 𝒖𝒑 𝒇𝒂𝒔𝒕—𝒓𝒆𝒔𝒆𝒓𝒗𝒆 𝒚𝒐𝒖𝒓𝒔 𝒕𝒐𝒅𝒂𝒚! #Webinar #pharma #drugdevelopment #ModelingAndSimulation #RegulatoryAffairs #Biosimilars #Generics #InSilico #biotechnology #LifeSciences #freewebinar InSilicoTrials

✨ 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐟𝐨𝐫 𝐚𝐧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐨𝐧 𝐀𝐈 𝐚𝐧𝐝 𝐌𝐨𝐝𝐞𝐥𝐢𝐧𝐠 & 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭! 🧑💻 We are excited to invite you to our upcoming webinar, 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐨𝐟 𝐀𝐈, 𝐚𝐧𝐝 𝐌𝐨𝐝𝐞𝐥𝐢𝐧𝐠 & 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭. Discover how #AI technologies with computational modeling are transforming the landscape of #drugdevelopment, particularly for #generics. 💊 🗓 Date: 27 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 2024 ⏰ Time: 10:00 𝐀𝐌 – 12:45 𝐏𝐌 𝐈𝐒𝐓 (𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐄𝐯𝐞𝐧𝐭) Our expert speakers, Mr. Nirnith Devireddy, Founder and CEO of InSilicoMinds, and Dr. Pranav Karmwar, Chief Scientific Officer at InSilicoMinds, will cover key topics, including: 🧑🔬 🔹Regulatory Acceptance of AI & CM&S 🔹CM&S for Long-Acting Injectables, Oral Dosage Forms & Biosimilars 🔹Predictive Modeling for Bioequivalence Studies 🔹CM&S for Monoclonal Antibodies and Biologics 🔹Case Studies & Regulatory Impact 🚀 𝑾𝒉𝒚 𝑨𝒕𝒕𝒆𝒏𝒅? This is a unique #opportunity to gain valuable insights into the regulatory and scientific advancements shaping the future of #pharmaceutical innovation. Whether you're involved in R&D, regulatory affairs, or drug development, this event promises to offer actionable #knowledge and strategic #approaches. 🔗 𝑹𝒆𝒈𝒊𝒔𝒕𝒆𝒓 𝑵𝒐𝒘: https://lnkd.in/gxfXp7S6 𝘞𝘦 𝘭𝘰𝘰𝘬 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘵𝘰 𝘴𝘦𝘦𝘪𝘯𝘨 𝘺𝘰𝘶 𝘵𝘩𝘦𝘳𝘦! 🤝 InSilicoTrials Federation of Asian Biotech Associations (FABA) Avicenna Alliance FDA Centers for Disease Control and Prevention #webinar #pharma #drugdevelopment #ModelingAndSimulation #RegulatoryAffairs #Biosimilars #Generics #InSilico #TelanganaLifeSciences #FDA #biotechnology #LifeSciences #freewebinar

In today's fast-paced pharmaceutical landscape, drug development faces numerous challenges—lengthy timelines, high failure rates, and immense costs. 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐰𝐞 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐞 𝐭𝐡𝐢𝐬 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐭𝐨 𝐦𝐚𝐤𝐞 𝐢𝐭 𝐦𝐨𝐫𝐞 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭? This is where artificial intelligence (AI) in computational modeling & simulation (M&S) is stepping in to reshape the future. 🧑💻 By #reducing development timelines and enabling precise predictive #modeling, AI has the power to revolutionize #drugdiscovery and #clinicaltrial designs. 💊 𝐁𝐮𝐭 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲? Beyond shorter #timelines and significant #savings, AI's unparalleled ability to analyze vast volumes of #data is reshaping computational modeling and simulation. With predictive accuracy reaching up to 90%, AI-driven M&S is revolutionizing early-stage drug discovery, clinical trial design, and regulatory submissions. These advancements empower researchers to make more informed, data-backed decisions—dramatically improving efficiency and reducing risk. This isn’t just a trend; it’s the future of pharmaceutical innovation. 🚀📈 ✨ InSilicoMinds paving the way for the future of pharmaceutical #innovation through AI-powered solutions—because better outcomes begin with smarter #strategies & #solutions. InSilicoTrials #AIinPharma #DrugDevelopment #ModelingAndSimulation #InSilicoMinds

𝐌𝐨𝐝𝐞𝐥𝐢𝐧𝐠 & 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 🧪💊 In generic drug development, leveraging data from approved products is key. Dr. Robert Lionberger, Director, Office of Research and Standards, Office of Generic Drugs at FDA, highlights the immense value modeling and simulation bring to this space, as it builds on existing #clinicaltrial data, offering a more efficient path to #market. By using modeling tools, the industry can #streamline development, #reduce risks, and consistently deliver affordable #medicines. This approach ensures faster reviews and consistent evaluation, benefiting both new and generic drug applications. Stay in touch with InSilicoMinds for more insights from industry thought leaders. ✨🧑🔬 InSilicoTrials #Pharma #FDA #ModelingAndSimulation #GenericDrugs #Innovation

🚀 𝐔𝐧𝐥𝐨𝐜𝐤 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐋𝐚𝐭𝐞𝐬𝐭 𝐔𝐊 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐨𝐧 𝐈𝐧 𝐒𝐢𝐥𝐢𝐜𝐨 𝐓𝐫𝐢𝐚𝐥𝐬! We are excited to share the key findings from the newly released report titled "𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝑷𝒐𝒘𝒆𝒓 𝒐𝒇 𝑪𝒐𝒎𝒑𝒖𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝑴𝒐𝒅𝒆𝒍𝒊𝒏𝒈 𝒂𝒏𝒅 𝑺𝒊𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝑨𝒄𝒓𝒐𝒔𝒔 𝒕𝒉𝒆 𝑷𝒓𝒐𝒅𝒖𝒄𝒕 𝑳𝒊𝒇𝒆𝒄𝒚𝒄𝒍𝒆 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆𝒔." Authored by leading experts from institutions like the The University of Manchester, Avicenna Alliance, and the #Medicines and #Healthcare Products #RegulatoryAgency, this comprehensive analysis addresses how in silico trials (ISTs) can revolutionize our approach to drug and device development. It's exciting to see thought leaders like Mark Palmer, M.D., Ph.D., Marc Horner, Ph.D., and Thierry Marchal contributing their invaluable insights to this impactful work. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 🔑 Utilization of ISTs can lead to up to 𝟲𝟬% 𝐟𝐚𝐬𝐭𝐞𝐫 development of new drugs and medical devices. As an example, Medtronic reported saving $𝟭𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 and reducing market access time by two years for its Micra leadless pacemaker through in silico simulations! 🌍 By 2025, manufacturers are expected to apply in silico methods in 𝟮𝟱% 𝗼𝗳 𝗻𝗲𝘄 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 and 𝟱𝟬% 𝗼𝗳 𝗻𝗲𝘄 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀, representing a 𝗴𝗹𝗼𝗯𝗮𝗹 𝗺𝗮𝗿𝗸𝗲𝘁 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗲𝗱 𝗮𝘁 $𝟭𝟬𝟵 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 for IST-enabled solutions! 📈 There’s an increasing recognition from regulatory bodies. The FDA and European Medicines Agency are both promoting modeling and simulation techniques to enhance approval processes, showing that the tide is turning towards embracing #digitalevidence in clinical evaluations. 🔬 𝘛𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘷𝘦 𝘐𝘮𝘱𝘢𝘤𝘵 𝘰𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘛𝘳𝘪𝘢𝘭𝘴: In silico trials are designed to #refine, #reduce, and occasionally #replace conventional human #clinicaltrials. They enable testing on virtual populations that can account for variability and complex patient characteristics, making it easier to predict #safety and #efficacy outcomes across diverse groups. ✨ There's so much more in this report than we can cover in a post! We encourage you to dive into the details and see how in silico technologies are set to reshape the future of #healthcare. 📚➡️ Read the full report here! https://lnkd.in/guvx3HD2 InSilicoTrials #InSilicoMinds #LifeSciences #Innovation #ClinicalTrials #ComputationalModeling #RegulatoryScience